| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/15/2014 | CN101778639B Proteinases destroy cancer tumor's solid structure and kill cancer cells locally |
| 01/15/2014 | CN101757609B Method for controlling residue of organic solvent in thymic peptide alpha1 microballoon |
| 01/15/2014 | CN101580547B Hasylated polypeptides, especially hasylated erythropoietin |
| 01/15/2014 | CN101559041B Polypeptide medicament sustained release microsphere or microcapsule preparation with uniform grain size and preparation method thereof |
| 01/14/2014 | US8630810 Modeling wound healing |
| 01/14/2014 | US8629253 Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis |
| 01/14/2014 | US8629241 Alpha helical mimics, their uses and methods for their production |
| 01/14/2014 | US8629240 Peptide ligands for clusterin and uses thereof |
| 01/14/2014 | US8629174 Unifying mechanism and methods to prevent cancer and neurodegenerative diseases |
| 01/14/2014 | US8629117 Method for stimulating the immune system |
| 01/14/2014 | US8629115 Compositions and methods for treating diseases |
| 01/14/2014 | US8629114 Compositions and methods for transport across the blood brain barrier |
| 01/14/2014 | US8629111 Methods of providing therapeutic effects using cyclosporin components |
| 01/14/2014 | US8629110 Kv1.3 channel blocking substances for the treatment of diseases associated with intimal hyperplasia |
| 01/14/2014 | US8629109 Method for promoting bone growth using activin-actriia antagonists |
| 01/14/2014 | US8629108 Rheumatoid arthritis T cell vaccine |
| 01/14/2014 | US8629107 Genes and proteins associated with angiogenesis and uses thereof |
| 01/14/2014 | US8629106 Affinity peptides toward BMP-2 |
| 01/14/2014 | US8629105 Pharmaceutical compositions for the treatment of movement disorders |
| 01/14/2014 | US8629104 G-CSF and water-soluble polymer conjugate |
| 01/14/2014 | US8629103 Treatment of non-proliferative cystic disease of the breast |
| 01/14/2014 | US8629102 3-hydroxyisothiazole 1-oxide derivatives |
| 01/14/2014 | US8629101 Cholesterol derivatives of inhibitors of viral fusion |
| 01/14/2014 | US8629098 Compositions and methods for adoptive and active immunotherapy |
| 01/14/2014 | US8629096 Compositions comprising fungal immunomodulatory protein and use thereof |
| 01/14/2014 | US8629088 Mixture of at least two fusion proteins, the production thereof and the use of the same |
| 01/14/2014 | US8628917 Genes of an otitis media isolate of nontypeable Haemophilus influenzae |
| 01/14/2014 | US8628791 Method of forming an implantable knitted fabric comprising silk fibroin fibers |
| 01/14/2014 | US8628781 Prevention and treatment of cast nephropathy |
| 01/14/2014 | US8628780 Lutzomyia longipalpis polypeptides and methods of use |
| 01/14/2014 | US8628775 Methods of reducing T cell-mediated immune responses with multimeric P-selectin and/or E-selectin compounds |
| 01/14/2014 | US8628770 Slimming cosmetic composition containing a substance inducing the production of IL-6 |
| 01/14/2014 | US8628769 Modified vitamin K-dependent polypeptides |
| 01/14/2014 | US8628767 Purine nucleoside phosphorylase as enzymatic activator of nucleoside prodrugs |
| 01/14/2014 | US8628754 Highly efficient delivery of a large therapeutic mass aerosol |
| 01/14/2014 | US8628572 Corneal endothelial scaffolds and methods of use |
| 01/14/2014 | CA2640343C Controlled production and delivery of biologically active agents by gut bacteria |
| 01/14/2014 | CA2563312C Plasmid mediated ghrh supplementation for renal failures |
| 01/14/2014 | CA2547869C Methods of protecting against radiation using flagellin |
| 01/14/2014 | CA2519875C Method of tumor regression with vegf inhibitors |
| 01/14/2014 | CA2504926C Compositions and methods for sirna inhibition of hif-1 alpha |
| 01/14/2014 | CA2426312C Compositions and methods for modulating rsv infection and immunity |
| 01/14/2014 | CA2418088C Numb protein expression inhibitors by musashi 1 |
| 01/14/2014 | CA2370252C Cancer treatment with endothelin receptor antagonists |
| 01/14/2014 | CA2342243C Stable liquid formulations of botulinum toxin |
| 01/09/2014 | WO2014008474A1 U1 snrnp regulates gene expression and modulates oncogenicity |
| 01/09/2014 | WO2014008465A2 Potentiation of antibiotic treatment with a protein-lipid complex |
| 01/09/2014 | WO2014008432A1 Cryopreservation of cells inside a macro-encapsulation device |
| 01/09/2014 | WO2014008385A1 Compositions and methods useful for making orthotopic tumors with controllable metastasis |
| 01/09/2014 | WO2014007661A1 Methods for determining personalized treatment compositions for prostate cancer and breast cancer |
| 01/09/2014 | WO2014007650A1 Compounds and methods for selective imaging and/or ablation |
| 01/09/2014 | WO2014007632A1 Cysteine protease capturing agents |
| 01/09/2014 | WO2014007584A1 Decoy peptides inhibiting protein phosphatase 1-mediated dephosphorylation of phospholamban |
| 01/09/2014 | WO2014007547A1 Novel peptides and use thereof |
| 01/09/2014 | WO2014007506A1 Igg fc position-selective binding peptides and hybrid molecules comprising same |
| 01/09/2014 | WO2014007402A1 Differentiation marker for and differentiation control for ocular cells |
| 01/09/2014 | WO2014007318A1 Cartilage cell growth promoter |
| 01/09/2014 | WO2014007266A1 Transdermal cancer antigen peptide preparation |
| 01/09/2014 | WO2014007228A1 Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes |
| 01/09/2014 | WO2014006645A1 Compositions for preventing and repairing skin and ocular damages caused by uv radiations |
| 01/09/2014 | WO2014006613A2 Plasminogen activator mutants as anti-fibrinolytic agents |
| 01/09/2014 | WO2014006502A1 Protozoan variant-specific surface proteins (vsp) as carriers for oral drug delivery |
| 01/09/2014 | WO2014006262A1 Composition containing polypeptides for the treatment of myiasis |
| 01/09/2014 | WO2014006253A1 Composition for treating bacterial infections of the skin and mucous membranes |
| 01/09/2014 | WO2014006114A1 New treatment for neurodegenerative diseases |
| 01/09/2014 | WO2014006113A1 Method of treating cancer by effective amounts of aflibercept |
| 01/09/2014 | WO2014006082A1 Conjugates containing sequences from placenta growth factor and their use as components of biomaterials and in medicine |
| 01/09/2014 | WO2014006063A2 Complement split product c4d for the treatment of inflammatory conditions |
| 01/09/2014 | WO2014005858A1 Use of long-acting glp-1 peptides |
| 01/09/2014 | WO2014005513A1 Cyclopeptide lhrh antagonist derivatives and pharmacal use thereof |
| 01/09/2014 | WO2014005466A1 Product for mitigating iron deficiency anemia and method for preparing same |
| 01/09/2014 | WO2014005241A1 Pharmacal use of angiostatin |
| 01/09/2014 | WO2014005183A1 Treatment of inflammatory skin disorders |
| 01/09/2014 | WO2013141759A3 Use of l-carnosine for the preparation of a nanopreparation having an antihypoxic and antioxidant activity |
| 01/09/2014 | WO2013130349A8 Variants of the lantibiotic mu1140 and other lantibiotics with improved pharmacological properties and structural features |
| 01/09/2014 | WO2013065078A3 Topical preparation containing ngf for inducing skin pigmentation and for the treatment of cutaneous dyschromias and vitiligo |
| 01/09/2014 | US20140012230 Method and apparatus for treatment of cardiac disorders |
| 01/09/2014 | US20140011977 Chimeric molecules to modulate gene expression |
| 01/09/2014 | US20140011821 Egfr mutations |
| 01/09/2014 | US20140011753 Cyclosporin compositions |
| 01/09/2014 | US20140011752 Prevention and treatment of ocular side effects with a cyclosporin |
| 01/09/2014 | US20140011751 Prevention and treatment of ocular side effects with a cyclosporin |
| 01/09/2014 | US20140011750 Prevention and treatment of ocular side effects with a cyclosporin |
| 01/09/2014 | US20140011749 Ketogenic diet composition for the treatment of chemo therapy and/or radiation therapy patients |
| 01/09/2014 | US20140011745 Organ preconditioning, arrest, protection, preservation and recovery (2) |
| 01/09/2014 | US20140011743 Human placental collagen compositions, and methods of making and using the same |
| 01/09/2014 | US20140011741 Hemoglobin compositions |
| 01/09/2014 | US20140011737 Compositions and methods for regulating metabolism |
| 01/09/2014 | US20140011736 Treatment for infection with hepatitis b virus alone or in combination with hepatitis delta virus and associated liver diseases |
| 01/09/2014 | US20140011733 Combination of acylated glucagon analogues with insulin analogues |
| 01/09/2014 | US20140011729 Methods of and compositions for inhibiting the proliferation of mammalian cells |
| 01/09/2014 | US20140011727 Methods of Evaluating Peptide Mixtures |
| 01/09/2014 | US20140010902 Excipient system for topical delivery of pharmaceutical agents |
| 01/09/2014 | US20140010864 Liposomes for protection against toxic compounds |
| 01/09/2014 | US20140010863 Liposomes for protection against toxic compounds |
| 01/09/2014 | US20140010862 Multifunctional biodegradable peg nanocarrier-based hydrogels for preventing hiv transmission |
| 01/09/2014 | US20140010859 Barley protein microcapsules |
| 01/09/2014 | US20140010857 Cell Preparations For Extemporaneous Use, Useful for Healing and Rejuvenation In Vivo |
| 01/09/2014 | US20140010846 Prevention and treatment of ocular side effects with a cyclosporin |
| 01/09/2014 | US20140010826 Use of DR6 and p75 Antagonists to Promote Survival of Cells of the Nervous System |